Cresco Labs Inc. (OTCMKTS:CRLBF – Free Report) – Research analysts at Atb Cap Markets increased their FY2025 earnings estimates for Cresco Labs in a research report issued to clients and investors on Monday, December 9th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings of ($0.07) per share for the year, up from their prior estimate of ($0.09). Atb Cap Markets currently has a “Hold” rating on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share.
A number of other research analysts have also issued reports on CRLBF. Cormark lowered Cresco Labs from a “moderate buy” rating to a “hold” rating in a report on Monday, November 11th. Roth Capital upgraded Cresco Labs to a “strong-buy” rating in a research note on Sunday, November 10th. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $2.50.
Cresco Labs Stock Performance
Shares of CRLBF stock opened at $0.98 on Wednesday. The firm has a 50 day moving average of $1.37 and a two-hundred day moving average of $1.57. The stock has a market capitalization of $475.94 million, a PE ratio of -4.88 and a beta of 1.73. The company has a quick ratio of 1.39, a current ratio of 1.97 and a debt-to-equity ratio of 1.80. Cresco Labs has a 52 week low of $0.96 and a 52 week high of $2.65.
About Cresco Labs
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Further Reading
- Five stocks we like better than Cresco Labs
- There Are Different Types of Stock To Invest In
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- Following Congress Stock Trades
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- Upcoming IPO Stock Lockup Period, Explained
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.